Serabelisib

Serabelisib (FTH-001, MLN1117) is a small-molecule drug developed by Faeth Therapeutics. Its target is PIK3CA / PI3K-alpha. ClinicalTrials.gov describes the intervention as: Serabelisib is a selective, small molecule inhibitor of PI3Kα. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in HR-positive / HER2-negative breast cancer and endometrial cancer. The largest, NCT06463028, plans to enrol 40 participants with primary completion expected 2028-09. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.